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Alzheimer’s disease (AD) is the most common form of dementia in the elderly. Although traditionally considered a disease of
neuroﬁbrillary tangles and amyloid plaques, structural and functional changes in the microvessels may contribute directly to the
pathogenesis of the disease. Since vascular dysfunction often precedes cognitive impairment, understanding the role of the blood-
brain barrier (BBB) in AD may be key to rationaltreatment of the disease. We propose that water regulation, a critical function of
the BBB, is disturbed in AD and results inabnormalpermeability and rates of water exchange across the vessel walls.In this paper,
we describe some of the pathological events that may disturb microvascular water exchange in AD and examine the potential of a
relatively new imaging technique, dynamic contrast-enhanced MRI, to quantify water exchange on a cellular level and thus serve
as a probe of BBB integrity in AD.
1.Introduction
Alzheimer’s disease (AD) is the most common form of ir-
reversibledementiaintheelderlyandaccountsformorethan
30% of all cases in adults over the age of 80 [1]. Patho-
logically, the disease is characterized by amyloid deposits,
neuroﬁbrillary tangles, and neuronal loss in speciﬁc brain
regions. Vascular involvement is not part of the diagnostic
criteria. Nevertheless, factors that modify vascular risk,
including hypertension, diabetes, and hypercholesterolemia,
areamongthemostconsistentlyidentiﬁedrisk factorsforthe
disease. Moreover, profound alterations in cerebrovascular
ultrastructureandfunctionhavebeenidentiﬁedinAD[2,3].
Since the microvessels are the key site for nutrient and
oxygen exchange between the brain and circulating blood,
it is likely that processes that disturb capillary physiology or
alter brain microcirculation are of major importance for the
pathogenesis of AD [4–6].
Morphologically, brain capillaries consist of a layer of
endothelial cells that line the luminal surface, pericytes, and
an outer basal membrane (Figure 1). In contrast to most
of the peripheral endothelia, endothelial cells in the CNS
form tight, unfenestrated junctions that restrict paracellular
diﬀusion of water, ions, and large molecules. Since other
mechanisms by which blood-borne substances cross into the
brain (e.g., carrier-mediated active or facilitated transport,
pinocytosis) are limited, these tight junctions limit the
diﬀusion of blood-borne solutes into the brain and are the
foundationoftheBlood-BrainBarrier(BBB)[7].Inaddition
to the endothelium, the functional integrity of the barrier is
also critically dependent on the basal lamina, pericytes, and
surrounding astroglia. The basal lamina provides structural
support for the endothelium, signals cell-cell interactions,
and separates the endothelium and pericytes from the
surrounding extracellular (interstitial) spaces. The pericytes,
closely associated with the abluminal surface of the basal
membrane, likely play a role in regulating microvascular
blood ﬂow and vascular remodeling [2]. Finally, the perivas-
cular astrocyte end-feet which ensheathe the outer surface of
the microvessels are of major importance in induction and2 Cardiovascular Psychiatry and Neurology
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Figure1:SchematicdiagramoftheBlood-BrainBarrier.Interstitial
ﬂuid ﬂows along perivascular drainage pathways deﬁned by the
abluminalcapillarysurface andastrocyte end-feet, which ensheathe
the vessels.
maintenance of the tight junctions, neurovascular coupling,
and ﬂuid balance [8, 9].
Approximately 90% of the blood volume in the brain
is water, and its exchange into and out of the blood is also
tightly regulated by the BBB. As in the periphery, water
in the CNS is highly compartmentalized and is present in
all brain compartments: intracellular and interstitial ﬂuids,
blood, and CSF. Increasing evidence suggests that functional
interactions between the cellular components of the BBB—
the endothelium, basal lamina, and pericytes—in addition
to the astroglial end-feet collectively regulate water exchange
between compartments, capillary blood volume, and perme-
ability. We hypothesize that microvascular water exchange
is disturbed in the AD brain as a result of an incompetent
BBB and is reﬂected in abnormal intercompartmental water
exchange. In this paper, we will provide the rationale for
our hypothesis and suggest a quantitative experimental
approach, dynamic contrast-enhanced magnetic resonance
imaging(DCE-MRI),bywhichwehaverecentlybeguntotest
this hypothesis in individuals with early cognitive changes.
2.The Pathophysiologyof Water
RegulationinAlzheimer’s Disease
The morphological footprint of BBB disturbances in AD
is clear. In the basal membrane, substantial thickening and
stiﬀening is observed in 90% of AD cases [10]. Macroscopi-
cally,thecapillariesappearthinandfragmented[11].Overall
density tends to be reduced, especially in important cortical
and hippocampal regions, and remaining vessels are more
tortuous. Inaddition, the endotheliumisfrequently atrophic
or swollen, and physical coupling to the surrounding glia
is often disrupted [12]. Moreover, the number of tight
junctions per unit of vessel length is reduced throughout the
brain [13–15] with metabolic regulation of remaining tight
junctions likely compromised by decreased, mitochondrial
density [14]. On a molecular level, the cell adhesion activity
of occludin and claudins, integral member proteins localized
exclusively to tight junctions, is decreased and accumulation
of collagen deposits, proteoglycans, laminins, and other
components of the basal matrix is frequently noted [16–18].
Despite the overwhelming abnormalities in capillary
structure and function, studies to deﬁne the temporal
association of microvascular changes with disease severity
and progression have not been done in humans, and the
extent to which BBB changes are likely to be symptomatic
of or causal to the disease remains unclear. Contributing to
the uncertainty is the variety of pathological environments
presentintheADbrain.Weexpect thatBBBfunctionismost
likelydisturbedastheresultofmultiplepathologicprocesses,
each of which may inﬂuence water exchange at the BBB, as
discussed brieﬂy in the following.
2.1. Cerebral Amyloid Angiopathy (CAA). Amyloid-β pep-
tides (Aβ) are derived from proteolytic cleavage of the
transmembrane amyloid precursor protein (APP) and vary
inlengthfrom39–43amino acids[19].InAD,depositsofAβ
characteristically accumulate in the parenchyma as plaques.
However, deposition of insoluble Aβ in the vessel walls and
interstitial spaces (as cerebral amyloid angiopathy (CAA))
occurs in nearly all individuals with AD [20]. Vascular
Aβ deposits are not always found in association with AD,
but, when they are found, they exhibit several important
diﬀerences from non-AD CAA [21]. In particular, the
deposits are most commonly associated with the capillaries,
where they attach to basal lamina and frequently occlude the
lumen and/or protrude into the interstitial space [22–24].
In addition, the deposits are enriched in Aβ1–42,t h es p e c i ﬁ c
isoforms of Aβ found in neuritic plaques [25].
Increasing evidence suggests that these deposits may
aﬀect BBB function in AD [26, 27]. In culture, exposure
of cortical microvessels to Aβ1–42 directly damages the
endothelium, resulting in an abnormal plasma membrane
pattern, reduced expression of tight junction protein com-
plexes, and increased permeability [28]. In vivo,t h e r ei s
clear evidence that vascular Aβ1–42 deposits are associated
with microhemorrhages. In the human AD brain, both
microhemorrhages and Aβ1–42 deposits are found close to or
encircling microvessels, show densities that covary through-
out the brain, and contain both blood- and vessel-derived
proteins (ﬁbrinogen, von Willebrand factor, collagen VI)
[29]. Moreover, recent studies in APP transgenic mice have
shown that increased vascular Aβ1–42 levels are associated
with decreased capillary density and abnormal basement
membrane protein composition, providing evidence that
Aβ1–42 accumulation is suﬃciently destructive to cause
loss of vessels in vivo [30]. Finally, on a macroscopic
scale, CAA-associated Aβ1–42 deposits essentially recapitulate
the perivascular drainage pathways [31, 32]. Thus, Aβ1–42
deposits build up around the same abluminal surfaces along
which interstitial ﬂuidiscleared,impeding diﬀusionofﬂuids
and further compromising the BBB’s ability to regulate water
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2.2.Inﬂammation. Blood-BrainBarrierfunctionmayalsobe
aﬀected by the inﬂammatory environment of AD microves-
sels [33]. Endothelial cells and astrocytes are activated
during inﬂammatory CNS disease and express a variety
of angiogenic mediators that aﬀect BBB permeability, as
demonstrated in other experimental models. For example,
inexperimental allergicencephalopathy,vascularendothelial
growth factor (VEGF-A) localized in reactive astrocytes is
upregulated and decreases expression of tight junction pro-
teins, converting the microvessels into permeable fenestrated
capillaries [34]. Importantly, aﬀected vessels are no more
permeable to proteins and macromolecules than those with
tight junctions but are much more permeable to water.
In AD, many microvessels express the same growth
factors, proteases, and proteins that typically characterize
an angiogenic response. However, the extent to which
expression of these factors is related to angiogenesis is
unclear [35–37]. APP transgenic mice overexpressing Aβ
exhibit impaired angiogenesis [38]. In the human AD brain,
both microvascular density [11, 39] and reduced blood
volume [40–42] are commonly observed. It is possible that
thegrowthfactorsandothermarkerstypicalofanangiogenic
response may in fact mediate an inﬂammatory one in the
context of the increased Aβ levels that characterize the AD
brain, with direct eﬀects on the BBB. Consistent with this,
Aβ has been shown to stimulate expression and activation of
metalloproteases that degrade a wide variety of extracellular
matrix components, resulting in loss of tight junctions and
BBB integrity [36, 43].
2.3. Aquaporins. In addition to inﬂammatory mediators,
astrocytes in the brain express aquaporin-4 (AQP4), one of
the family of water channels found in plasma membranes
throughout the body [44–48]. Functionally, aquaporins
regulate transmembrane water permeability in response to
osmotic gradients. In the brain, AQP4 is localized to tissue-
ﬂuid interfaces: in the glia limitans (pia-subarachnoid CSF),
the ependyma (ependymal lining-ventricular CSF), and at
theBBBinthe astrocyte foot processes and, toalesser extent,
the endothelium [48]. The expression of AQP4 speciﬁcally
at the borders of ﬂuid-ﬁlled compartments suggests an
important role of these channels in water homeostasis, a role
now conﬁrmed by many groups [45, 49–52].
While evidence linking aquaporins with ﬂuid regulation
inconditionsassociated with brainedemais nowsubstantial,
the eﬀect of neurodegenerative disease on aquaporins and
the consequences to BBB function remain to be deﬁned
[44]. At present, the extent to which AQP4 pathophysiology
contributes to structural abnormalities in the BBB has not
been established [53, 54]. Nevertheless, Wilcock et al. have
recently found that AQP4 localization to the perivascular
end-feet is signiﬁcantly reduced in APP transgenic mice with
high vascular Aβ, as is the density of astrocyte end-feet
in close contact with vessel wall [55]. That only minimal
changes were observed in APP transgenics with low Aβ load
suggests that aquaporin function may be altered at the BBB
in AD and may be a consequence of Aβ deposition in the
microvessels.
3.Dynamic Contrast-EnhancedMagnetic
Resonance Imaging (DCE-MRI)
The experimental index of BBB integrity has traditionally
been based on the exclusion of blood-borne molecules
(e.g., albumin or horseradish peroxidase) for which BBB
transport mechanisms are poor. In the case of albumin,
a 70kDa serum protein, the albumin transporter is nearly
absent in brain endothelium, while horseradish peroxidase
is rarely found in the parenchyma due to the absence of
pinocytotic vesicles [4, 56]. The presence of low molecular
weightdyesinthecerebrospinalﬂuid(CSF)afterintravenous
injection has also been used to probe BBB compromise.
While methodologically simpler, these experiments can be
diﬃcult to interpret as detailsrelated to dye stability, binding
mechanisms, and speciﬁc eﬀects on vascular morphology
are generally lacking. Nevertheless, an age-related increase
in Evans blue and carboxyﬂuorescein has been observed
in the cortex of APP transgenic mice overexpressing Aβ
following rapid intraperitoneal injection [57]. Importantly,
changes in permeability appeared in young mice, before Aβ
deposition, consistent with BBB changes early in the disease
process. However, ﬁndings have not been universal and in
doubletransgenics overexpressing APPand presenilin1,part
of the γ-secretase complex responsible for APP cleavage,
bolus infusion of neither albumin nor 125I-insulin showed
increased permeability compared to age-matched controls
[58].
Assessment of BBB function in AD patients has been
limited for the most part to analysis of cerebrospinal ﬂuid
(CSF) content. Here, too, data are conﬂicting, and albumin
levels signiﬁcantly diﬀerent from those of age-matched
controls have not been consistently identiﬁed [59, 60].
Nevertheless, an increased CSF-albumin index has been
reported in subsets of AD patients by several groups [60].
Additionally, Bowman et al. recently found a signiﬁcant
correlation of CSF-albumin index with the rate of disease
progression in a subset of patients with mild-to-moderate
AD [61]. This ﬁnding suggests that BBB dysfunction may
increase the rate of disease progression in at least some AD
patients.
In contrast to this more traditional approach, dynamic
MRI techniques provide quantitative measures of BBB
integrity based on changes in the water proton ( 1H2O)
longitudinal or transverse relaxation rate constants, R1 and
R∗
2 , respectively, during bolus passage of a low molecular
weight paramagnetic contrast reagent (CR). Dynamic sus-
ceptibility contrast (DSC) MRI, is based on measurement
of R∗
2 (= 1/T∗
2 )e ﬀects and has been used by many groups
to characterize perfusion changes in the AD brain [62–65].
R
∗
2 eﬀects can be exquisitely sensitive to pathophysiological
changes, but their interpretation on a molecular level can
be challenging. Changes in R∗
2 are strongly inﬂuenced by
bulk magnetic susceptibility eﬀects. These eﬀects are long
range and vary depending on the size, shape, and orientation
of the local magnetic ﬁeld [66]. As a result, susceptibility
eﬀects not only cross tissue compartment boundaries but
vary substantially on the histological scale, which is small
with respect to an MRI voxel [67–69]. Susceptibility eﬀects,4 Cardiovascular Psychiatry and Neurology
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Figure 2: Schematic diagram of the three-compartment model
of tissue. EES: extravascular extracellular space; EIS: extravas-
cular intracellular space; τ
−1
b : unidirectional rate constant for
water extravasation; Ktrans: pseudo-ﬁrst-order rate constant for CR
extravasation.
therefore, can make analytical interpretation of DSC-MRI
problematic and result in large errors in pharmacokinetic
estimates derived from DSCmeasurements [70]. In contrast,
DCE-MRI is based on R1 (= 1/T1) changes. These occur
from direct contact of 1H2Ot oC Ra n da r en o ti n ﬂ u e n c e db y
bulk magnetic susceptibility [71]. As a result, the 1H2O R1
value in a given compartment is unaﬀected by CR in an
adjacent compartment except by intercompartment 1H2O
exchange. Thus, R1 changes during bolus CR passage can
be interpreted analytically to provide a quantitative mea-
sure of intercompartmental water dynamics. Changes in
tissue water compartmentalization have been shown to be
an extremely sensitive and early indicator of BBB break-
down in multiple sclerosis, tumors, and other pathologies
[72–74].
The accuracy of DCE-MRI parameters depends critically
on the pharmacokinetic model used to ﬁt the tissue R1
changes (ΔR1t) after CR injection. To a ﬁrst approximation,
biological tissue can be described by three compartments:
blood, extravascular extracellular (EES), and extravascular
intracellular space (EIS) (Figure 2). In each compartment,
CRand 1H2Oareassumedtobewellmixed.Inhealthybrain,
1H2O (which forms the basis for the MR signal) occupies
and exchanges between all three compartments, while low
molecular weight contrast reagents do not permeate cell
membranes and are restricted to the plasma and EES [67–
69]. Immediately after injection, CR is conﬁned to the
plasma and greatly increases the R1 of 1H2O in the blood,
R1b( 1H2O exchange between erythrocytes and plasma is fast
on the MR timescale, and the amount of 1H2O in blood can
bemodeledusingthehematocritvolumefraction)[75].Over
time, CRdiﬀuses through thevessel wall and increases the R1
of 1H2O in the extravascular space. Thus, the mathematical
relationship between R1b and R1t depends not only on
the kinetics of compartmental 1H2Oe x c h a n g eb u ta l s oo n
the rate at which CR leaks through the vessel wall (Ktrans)
[76].
In the limit of small Ktrans (< 10
−4 min
−1), as is the case
for studies of normal and near-normal BBB permeability, a
model with only two compartments is suﬃcient to describe
transendothelial 1H2O exchange. In this two-site model, it
is assumed that CR is initially conﬁned to the blood plasma
and that 1H2O freely exchanges between the plasma and a
combined (EES and EIS) extravascular space. Since most of
the 1H2O MRI signal originates from theextravascular space
(in white matter, the blood 1H2Os i g n a li sl e s st h a n2 %o f
the total signal), it is further assumed that R1t exhibits single
exponential behavior.Atearly times afterCRadministration,
the time dependence of R1t changes depend primarily on
changes in R1b, and hence on the concentration of CR in
the blood (CRb); [CRb] is a ﬁctious concentration since CR
d i s t r i b u t e so n l yi n t ot h ep l a s m a ,s oi ti su s e f u lt or e c a s tt h i s
in terms of [CRp]:
R1b(t) = r1[CRb](t) +R1b0 = r1 (1 − h)
 
CRp
 
(t) + R1b0,
(1)
where r1 is the longitudinal relaxivity of CR, R1b0 is the R1 of
blood 1H2O before CR injection and h is the hematocrit.
CRextravasationalsocontributestothetimedependence
of ΔR1t, and this is accounted for by a time-varying
extravascular R1 (≡ R1e) component. As CR permeates the
BBB, it passes into the EES (see Figure 2). If Ktrans is small,
though, CR never achieves suﬃcient concentration to drive
the EIS-EES water exchange. Under these conditions, the
linear relationship of (2) applies. Here, [CREES]i st h ec o n -
centrationofCRintheEES.Undertheseconditions,thetime
dependence of [CREES], and hence R1e, is determined by the
Kety-Schmidt integral rate law [72, 79, 80]. Manipulation
of these two equations yields the (nonlinear) relationship
between R1b and R1t for two-site transendothelial exchange
shown in (3)[ 67–69]. Fits of R1b and R1t to (3)y i e l dn o t
only vb, the cerebral blood volume (vb = pb fw,w h e r efw is
the tissue volume accessible to mobile solutes (ca. 0.8)), but
τ−1
b , the rate constant for water extravasation. τ−1
b and the
related permeability-surface area product of water, PwS (=
vb/τb), represent quantitative measures of capillary water
permeability and are direct measures of BBB integrity. Here
we assume that r1 is independent of compartment:
R1e(t) = r1ve[CREES](t)+ R1e0, (2)
where ve is the extravascular extracellular volume fraction
and R1e0 is the R1 of the extravascular 1H2Ob e f o r eC Ri n -
jection and without transendothelial exchange,
R1t(t) =
1
2
⎧
⎨
⎩
 
R1b(t)+ R1e + τ
−1
b +
pb
τb
 
1 − pb
 
 
−
⎡
⎣
 
R1e −R1b(t) − τ
−1
b +
pb
τb
 
1 − pb
 
 2
+
4pb
τ2
b
 
1 − pb
 
⎤
⎦
1/2⎫
⎪ ⎬
⎪ ⎭
,
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Figure 3:DCE-MRI regionofinterest(ROI) analysisinthe centrum semiovale(CSO)ofa 73-year-old healthyfemale.(a)AxialT1-weighted
(turboFLASH) imageswere collected ona Siemens7Tsystem with8-channel phasedarraytransmit/receive headcoil;selected ROI shownin
white. (b) Plot of pre-post contrast R1t (ΔR1t) versus time. Images were collected immediately preceding two 0.05mmol/kg bolus injections
of gadoteridol and every 2.5 seconds over the next 175sec. R1t values were calculated at each time point by ﬁtting the signal intensity curves
to a standard two-parameter single exponential inversion recovery equation [77]. (c) ΔR1t plotted as a function of ΔR1b.C h a n g e si nt h e
blood signal, ΔR1b, were determined from an ROI placed entirely in the sagittal sinus. The solid line represents the best ﬁt of the data to (3).
Resultant estimates of vb, τ
−1
b ,a n dPwS are also shown.
where R1t0, R1b0 are the R1 of tissue and blood, respectively,
before CR injection, R1e is the R1 of extravascular water in
the absence of transendothelial exchange, τb is the average
intravascular lifetime, and pb is the mole fraction of blood
water.
PreviousDCE-MRIstudiesinADindividualshavefound
minimal disruption of the BBB [81, 82]. However, these
studies are limited by the relatively low ﬁeld strength (1.5T)
of the measurements and the lack of pharmacokinetic mod-
eling. The real power of DCE to probe BBB disturbances,
particularly in the context of a relatively intact barrier, is
most evident at high ﬁeld, where the increased signal-to-
noise and reduced CR detection threshold yields signif-
icantly better precision and accuracy of pharmacokinetic
estimates. Figure 3 shows a representative 7T DCE-MRI
study performed recently in our laboratory. Fitting to (3)
yields values of τ
−1
b and vb in the centrum semiovale that are
in close agreement with those reported previously [83, 84].
Application of (3) on a pixel-wise basis results in parametric
maps like the ones shown in Figure 4(a) [78]. As far as we
are aware, this is the ﬁrst map of the water permeability
surface area product (PwS) produced using dynamic MR
techniques in an individual with early AD, and underscores
the power of DCE to visualize even subtle changes in BBB
water permeability (Figure 4(b)).
It should be noted that use of (3) can lead to large errors
in parametric estimates if 1H2O exchange across the BBB
or extravascular cell membranes (i.e., between EES and EIS
in Figure 2) is slow on the timescale of DCE measurements
[85]. In either of these situations, abstraction of accurate
parameters requires a three-compartment model and a more
comprehensive pharmacokinetic treatment. Such a model6 Cardiovascular Psychiatry and Neurology
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Figure 4: 7T (a) DCE-MRI maps of blood volume (vb) and water permeability (PwS) in a superior slice from a 71-year-old female with
early AD [78].(b) T2-weighted spin echo imageand corresponding pb mapfrom a healthy 70-year-old female.Arrows indicate hyperintense
white matter regions (15–23mm2) visible on both the T2 image and corresponding parametric map.
has been developed by Li et al. and is currently being applied
in our laboratory [76].
4.Conclusion
The BBB plays a critical role in water homeostasis in the
brain. Although the mechanism remains to be determined,
converging evidence suggests that AD pathophysiology may
disturb the BBB and disrupt intercompartmental water
exchange. DCE-MRI is an extremely powerful and sensitive
probeofwaterdynamics inthelivingbrain.Pharmacokinetic
modeling provides quantitative estimates of blood volume,
vascular permeability, and rates of transendothelial water
exchange. We expect that DCE-MRI studies, particularly at
high ﬁeld, will play a key role in unlocking the contribution
of BBB dysfunction to the pathophysiology of AD.
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